Skip to main content

Accuracy and Precision of Bioanalytical Assays

 Accuracy and precision are fundamental aspects of bioanalytical assay validation. Accuracy refers to how close the measured values are to the true or reference values, while precision assesses the consistency of measurements when repeated under the same conditions. Here's how accuracy and precision are typically performed and evaluated:

Accuracy:

Reference Standard: A certified reference standard of the analyte is used to establish the true concentration. The reference standard's concentration is accurately known and traceable to a recognized standard.

Spiking: A set of samples containing the analyte at various concentrations is prepared by spiking known amounts of the reference standard into a matrix that closely resembles the samples being analyzed.

Analysis: Both the spiked samples and the unspiked samples (blank matrix) are analyzed using the bioanalytical assay. The goal is to measure the analyte's concentration accurately.

Calculation: The accuracy is calculated by comparing the measured concentrations of the spiked samples to the known reference standard concentrations. Accuracy is expressed as a percentage recovery, where recovery close to 100% indicates high accuracy.

Acceptance Criteria: Regulatory guidelines or predefined criteria determine acceptable accuracy ranges. The assay's accuracy should fall within these ranges for reliable data interpretation.


Precision:

Replicate Analysis: Multiple aliquots of the same sample are analyzed in a single analytical run or across multiple runs. Each aliquot is treated as an independent measurement.

Calculation of Variability: The variability of the measurements is assessed through statistical analysis. Common parameters used to assess precision include the standard deviation (SD), coefficient of variation (CV), and relative standard deviation (RSD).

Within-Batch Precision (Repeatability): Within a single analytical run, the precision is evaluated by calculating the SD, CV, or RSD of the measurements from replicates of the same sample.

Between-Batch Precision (Intermediate Precision): Precision is evaluated by analyzing replicates of the same sample across multiple analytical runs. The SD, CV, or RSD is calculated to assess the variability across different days or instruments.

Acceptance Criteria: Similar to accuracy, predefined acceptance criteria or regulatory guidelines dictate acceptable precision levels. Lower variability (smaller SD, CV, or RSD) is desirable for reliable and reproducible results.

Evaluation of System Suitability: 

System suitability tests ensure that the analytical system is performing as expected. These tests may include analyzing quality control samples across the analytical run to ensure consistent performance.

Data Interpretation: The precision assessment helps researchers understand the level of variability inherent in the assay. High precision indicates that the assay can produce consistent results under the same conditions.

Labels:

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

Allometric scaling in AAV gene therapy dose estimation

 Allometric scaling in AAV gene therapy dose estimation is crucial for translating effective and safe doses from animal models to humans. Since AAV dosing often involves high viral vector concentrations, proper dose scaling is essential to minimize adverse effects and optimize therapeutic outcomes. Here’s a breakdown of how allometric scaling is applied in AAV gene therapy dosing and the considerations involved: 1. Concept of Allometric Scaling Allometric scaling is a method of adjusting drug doses across species based on body size, physiology, and metabolism. It is especially useful in biologics and gene therapies where the pharmacokinetics and pharmacodynamics are more complex than small-molecule drugs. For AAV vectors, dosing is commonly scaled by body weight (e.g., vector genomes [vg] per kilogram) or body surface area (BSA), as these parameters can approximate dose distribution and vector exposure across different species. 2. Standard Scaling Approaches Body Weight Scaling (mg...
Read more

Cell-Mediated Immunity in AAV Gene Therapy

Cell-mediated immunity (CMI) plays a significant role in the effectiveness and safety of AAV (Adeno-Associated Virus) gene therapy. Understanding the impact of CMI is crucial for optimizing therapeutic outcomes and managing potential adverse effects. Here’s a detailed overview of the impact of CMI on AAV gene therapy: 1. Mechanisms of Cell-Mediated Immunity in AAV Gene Therapy T-Cell Activation : After administration of an AAV vector, T cells can recognize the AAV capsid proteins or the transgene product as foreign antigens, leading to their activation. This can involve both CD4+ helper T cells and CD8+ cytotoxic T cells. Cytokine Production : Activated T cells produce cytokines (e.g., IFN-γ, TNF-α) that can enhance the immune response. These cytokines can influence the activation and proliferation of other immune cells, including B cells and macrophages. 2. Impact on Efficacy of AAV Gene Therapy Enhanced Antigen Presentation : CMI can improve the presentation of transgene-derived anti...
Read more